Supplement

You have full text access to this OnlineOpen article

Distribution of treatment for human papillomavirus-associated gynecologic carcinomas before prophylactic vaccine†‡

  1. Serban Negoita MD, DrPH1,§,*,
  2. Jovanka N. Harrison PhD1,
  3. Baozhen Qiao MD, PhD1,
  4. Donatus U. Ekwueme PhD2,
  5. Lisa C. Flowers MD3,
  6. Amy R. Kahn MS1

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23751

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2926–2935, 15 November 2008

Additional Information

How to Cite

Negoita, S., Harrison, J. N., Qiao, B., Ekwueme, D. U., Flowers, L. C. and Kahn, A. R. (2008), Distribution of treatment for human papillomavirus-associated gynecologic carcinomas before prophylactic vaccine. Cancer, 113: 2926–2935. doi: 10.1002/cncr.23751

Author Information

  1. 1

    New York State Cancer Registry, New York State Department of Health, Albany, New York

  2. 2

    Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

  3. 3

    Department of Gynecology and Obstetrics, School of Medicine, Emory University, Atlanta, Georgia

  1. §

    Fax: (518) 473-6789.

*New York State Cancer Registry, New York State Department of Health, Empire State Plaza, Corning Tower, Room 536, Albany, NY 12237-0679

  1. †

    We appreciate the thorough review by Dr. Cyril Spann.

  2. ‡

    The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 16 JUN 2008
  4. Manuscript Revised: 5 JUN 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Centers for Disease Control and Prevention's Cooperative Agreement. Grant Number: U58/DP000783-01
  • New York State Department of Health
  • National Program of Cancer Registries
  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (150K)

REFERENCES

  • 1
    Daling JR,Madeleine MM,Schwarts SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263–270.
  • 2
    Hildesheim A,Han CL,Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancers: results from a seroepidemiological case-control study. Obstet Gynecol. 1997; 90: 748–754.
  • 3
    Walboomers J,Jacobs M,Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–19.
    Direct Link:
  • 4
    Bosch FX,Manos MM,Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a world wide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 779–780.
  • 5
    Singh GK,Miller BA,Hankey BF,Edwards BK. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 1051–1057.
    Direct Link:
  • 6
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10: 31–46.
    Direct Link:
  • 7
    Saraiya M,Ahmed F,Krishnan S,Richards TB,Unger ER,Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007; 109: 360–370.
  • 8
    Patel DA,Barnholtz-Sloan JS,Patel MK,Malone JMJr,Chuba PJ,Schwartz K. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol. 2005; 97: 550–558.
  • 9
    Howe HL,Wu X,Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006; 107: 1711–1742.
    Direct Link:
  • 10
    Wang SS,Sherman ME,Hildesheim A,Lacey JVJr,Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004; 100: 1035–1044.
    Direct Link:
  • 11
    Trimble EL,Harlan LC,Clegg LX. Untreated cervical cancer in the United States. Gynecol Oncol. 2005; 96: 271–277.
  • 12
    Goldie SJ,Grima D,Kohli M,Wright TC,Weinstein M,Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003; 106: 896–904.
    Direct Link:
  • 13
    Barnabas RV,Laukkanen P,Koskela P,Kontula O,Lehtinen M,Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. PLoS Med [serial online]. 2006; 3: e138.
  • 14
    Shi L,Sings HL,Bryan JT, et al. GARDASIL®: prophylactic human papillomavirus vaccine development—from bench top to bed-side. Clin Pharmacol Ther. 2007; 81: 259–264.
  • 15
    Quinn MA,Benedet JL,Odicino F, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( suppl 1): S43–S103.
  • 16
    Beller U,Quinn MA,Benedet JL, et al. Carcinoma of the vulva. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( ):suppl 1 S7- S27.
  • 17
    Beller U,Benedet JL,Creasman WT, et al. Carcinoma of the vagina. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( suppl 1): S29–S42.
  • 18
    National Cancer Institute. PDQ Adult Treatment Summaries. Available at: http://www.cancer.gov/cancertopics/pdq/adulttreatment. Accessed October 14, 2007.
  • 19
    Eifel PJ,Moughan J,Erickson B,Iarocci T,Grant D,Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2004; 60: 1144–1153.
  • 20
    Katz A,Eifel PJ,Moughan J,Owen JB,Mahon I,Hanks E. Socioeconomic characteristics of patients with squamous cell carcinoma of the uterine cervix treated with radiotherapy in the 1992-1994 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2000; 47: 443–450.
  • 21
    Mundt AJ,Connell PP,Campbell T,Hwang JH,Rotmensch J,Waggoner S. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol. 1998; 71: 151–158.
  • 22
    del Carmen MG,Montz FJ,Bristow RE,Bovicelli A,Cornelison T,Trimble E. Ethnic differences in patterns of care stage 1a and stage 1A cervical cancer: a SEER database study. Gyneocol Oncol. 1999; 75: 113–117.
  • 23
    Buchler JW. Surveillance. In: RothmanKJ,GreenlandS, eds. Modern Epidemiology.2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998: 435–458.
  • 24
    National Cancer Institute. Surveillance, Epidemiology, and End Results Program. NIH Publication No. 05-4772. Bethesda, MD: National Cancer Institute; 2005.
  • 25
    Surveillance, Epidemiology, and End Results (SEER) Program. Incidence—SEER 17 Registries Limited-Use (released April 2007, based on the November 2006 submission). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, 2007.
  • 26
    Watson M,Saraya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of cancer in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2841–2854.
    Direct Link:
  • 27
    Commission on Cancer. Facility Oncology Registry Data Standards. Revised for 2007. Chicago, Ill: American College of Surgeons; 2007. Available at: http://www.facs.org/cancer/coc/fordsmanual.html. Accessed October 24, 2007.
  • 28
    GreeneFL,PageDL,FlemingID, et al, eds. Cervix uteri. AJCC Cancer Staging Handbook,6th ed. Chap 28. New York: Springer-Verlag; 2002: 293–305.
  • 29
    JohnsonCH, ed. SEER Program Coding and Staging Manual 2004. Publication No. 04-5581. Bethesda, MD: National Institutes of Health; 2004.
  • 30
    SAS Institute. SAS OnlineDoc® 9.1.2. Cary, NC: SAS Institute Inc.; 2004.
  • 31
    National Cancer Institute. Joinpoint Regression Program, Version 3.0. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2005. Available at: http://srab.cancer.gov/joinpoint/. Accessed October 7, 2007.
  • 32
    Luke C,Nguyen AM,Heard A,Kenny B,Shorne L,Roder D. Benchmarking epidemiological characteristics of cervical cancer in advance of change in screening practice and commencement of vaccination. Aust N Z J Public Health. 2007; 31: 149–154.
    Direct Link:
  • 33
    The NCCN Guideline Cervical Cancer. Clinical Practice Guidelines in Oncology. Version I. 2008. National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed March 11, 2008.
  • 34
    Beckmann CRB,Ling FW,Laube DW,Smith RP,Barzansky BM,Herbert WNP. Vulvar and vaginal disease and neoplasia. In: Obstetrics and Gynecology, 4th ed. Chap 43. Hagerstown, MD: Lippincott Williams & Wilkins; 2002: 533–567.
  • 35
    Babalola EO,Bharucha AE,Schleck CD,Gebhart JB,Zinsmeister AR,Melton LJ. Decreasing utilization of hysterectomy: a population-based study in Olmstead County, Minnesota, 1965-2002. Am J Obstet Gynecol. 2007; 196: 214.e1–214.e7.
  • 36
    Jackson KS,Naik R. Pelvic floor dysfunction and radical hysterectomy. Int J Gynecol Cancer. 2006; 16: 354–363.
    Direct Link:
  • 37
    Saraiya M,Lee NC,Blackman D,Smith MJ,Morrow B,McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol. 2001; 98: 269–278.
  • 38
    Hewitt M,Devesa SS,Breen N. Cervical cancer screening among US women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270–278.
  • 39
    Powell LH,Meyer P,Weiss G, et al. Ethnic differences in past hysterectomy for benign conditions. Womens Health Issues. 2005; 15: 179–186.
  • 40
    Phillips JM,Cohen MZ,Moses G. Breast cancer screening and African-American women: fear, fatalism, and silence. Oncol Nurs Forum. 1999; 26: 561–571.
  • 41
    Hakim RB,Benedict MB,Merrick NJ. Quality of care for women undergoing a hysterectomy: effects of insurance and race/ethnicity. Am J Public Health. 2004; 94: 1399–1405.
  • 42
    Brooks SE,Ahn J,Mullins CD,Baquet CR,D'Andrea A. Healthcare cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma. Cancer. 2001; 92: 950–958.
    Direct Link:
  • 43
    Becker ER,Spalding J,DuChane J,Horowitz IR. Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998-2002. J Natl Med Assoc. 2005; 97: 1336–1342.
  • 44
    Fetters MD,Lieberman RW,Abrahamse PH,Sanghvi RV,Sonnad SS. Cost-effectiveness of Pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis. 2003; 7: 194–202.
  • 45
    Brown ML,Riley GF,Schussler N,Etzioni R. Estimating healthcare cost from SEER-Medicare data. Med Care. 2002; 40( suppl IV): 104–117.
  • 46
    Follen M,Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst. 2000; 92: 363–365.
  • 47
    Insinga RP,Dasbach EJ,Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23: 1107–1122.
  • 48
    Chesson HW,Blandford JM,Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004; 36: 11–19.
    Direct Link:
View Full Article (HTML) Get PDF (150K)